Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Montelukast · Singulair, MK-0476A

Small molecule · Antagonist of cysteinyl leukotriene type-1 receptor (CYSLTR1) · developed by Organon

Approved FDA, Feb 1998
OGN Developer
1 Registered trials

What is Montelukast?

Montelukast is an orally active leukotriene receptor antagonist that binds with high affinity and selectivity to the cysteinyl leukotriene 1 (CysLT1) receptor, blocking the inflammatory actions of leukotriene D4. It is studied in allergic rhinitis, where cysteinyl leukotrienes released from the nasal mucosa contribute to symptoms.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Singulair, MK-0476A
Drug type
Small molecule
Targets
cysteinyl leukotriene type-1 receptor (CYSLTR1)
Mechanism
Antagonist of cysteinyl leukotriene type-1 receptor (CYSLTR1)
Pathways
leukotriene signaling, eosinophil and mast cell-mediated inflammation, airway smooth muscle contraction
Therapy area
Immunology, Respiratory
Developer
Organon (OGN)
Also in trials of
SNY
FDA status
Approved as Singulair (February 20, 1998), NDA020829 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Apr 30, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01673620 Phase 3 Allergic Rhinitis Completed OGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Allergic Rhinitis

More from Organon

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the OGN page.

Follow OGN, the company behind Montelukast

See OGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

OGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.